
Question: Can a pharmacist be held legally responsible if they dispense a substandard or counterfeit drug that was supplied to them by a licensed distributor? Does the pharmacist’s liability depend on knowledge, due diligence, or regulatory compliance?
Case scenario
A patient visits a pharmacy in Abuja to purchase an antibiotic prescribed for a serious infection. The pharmacist sources the drug from a licensed distributor. Unknown to both parties, the batch contains a substandard product with insufficient active ingredients. The patient’s condition worsens, leading to hospitalisation.
The patient’s family threatens legal action, claiming negligence on the part of the pharmacist for selling an ineffective medication. The pharmacist argues that the supplier was licensed, the product bore all required regulatory markings, and standard verification procedures were followed.
Legal perspective
Under Nigerian law, pharmacists are regulated by professional and statutory standards requiring that they dispense safe, effective medications. Liability in cases of substandard or counterfeit drugs supplied by a licensed distributor hinges on several considerations:
Professional duty of care: Pharmacists must act with reasonable care to ensure that dispensed medicines meet safety and quality standards.
Supplier verification: While licensed distributors are presumed trustworthy, pharmacists are expected to exercise due diligence, including verifying supplier credibility and batch documentation.
Regulatory compliance: Adherence to NAFDAC registration, labelling, and storage requirements is critical.
Knowledge and intent: Liability is more likely if the pharmacist knew or should have known the drug was substandard, or if there was gross negligence in verification.
Causation and harm: Courts will examine whether the substandard product directly caused harm and whether the pharmacist’s actions contributed to the outcome.
Pharmacists are not automatically liable for all defective medicines obtained from licensed suppliers. Liability generally arises if there is a failure to exercise professional judgment, due diligence, or adherence to regulatory requirements.
Determining liability
Factors courts consider include:
Due diligence: Verification of the supplier’s licence, product authenticity, and NAFDAC registration.
Record-keeping: Documentation of procurement, batch numbers, and storage conditions.
Professional standards: Compliance with pharmacy practice codes and national regulations.
Patient communication: Any warnings or advice given about potential risks.
Foreseeability of harm: Could the pharmacist reasonably have anticipated the risk?
Liability is more likely if the pharmacist failed to act with care or ignored warning signs, even when using licensed suppliers.
Defences available to pharmacists and healthcare providers
Good faith procurement: Product obtained from a licensed, NAFDAC-approved distributor.
Due diligence: Standard verification procedures followed.
Lack of knowledge: No reasonable way to detect substandard product before dispensing.
Regulatory compliance: All storage, labelling, and dispensing protocols met.
Absence of contributory negligence: Harm resulted solely from the product defect, not the pharmacist’s handling.
Practical advice
Source drugs exclusively from reputable, licensed distributors.
Maintain accurate records of supplier details, batch numbers, and delivery receipts.
Inspect packaging for regulatory markings, expiry dates, and tampering.
Educate pharmacy staff on identifying suspicious or counterfeit products.
Establish an internal reporting and recall protocol in case defective drugs are discovered.
Communicate transparently with patients if any concerns about quality arise.
Closing insight
Pharmacists are the final safeguard for patient safety in the drug supply chain. While liability for substandard or counterfeit drugs from licensed suppliers is not automatic, Nigerian law and professional codes require pharmacists to exercise vigilance, document procurement practices, and act in good faith. Diligence, verification, and clear patient communication remain the strongest protections against legal risk.



